Posted by Michael Wonder on 18 May 2022
Alnylam announces Health Canada authorisation of Oxlumo (lumasiran), the first and only treatment for primary hyperoxaluria type 1 to lower urinary oxalate levels in paediatric and adult patients
18 May 2022 - Authorization based on two pivotal Phase 3 trials, ILLUMINATE-A and ILLUMINATE-B; showing significant reduction in urinary oxalate which drives the progression of primary hyperoxaluria type 1 disease.
Alnylam Pharmaceuticals is pleased to announce that Health Canada has issued a Notice of Compliance authorising Oxlumo (lumasiran) injection for subcutaneous use for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate levels in paediatric and adult patients.
